Pharmacologic Appetite Stimulation in Older Adults with Cardiovascular Risk

First‑Line Alternative: Mirtazapine

For older adults with cardiovascular risk factors who cannot tolerate megestrol acetate, low‑dose mirtazapine (7.5 mg nightly) is the preferred first‑line option, especially when depression or sleep disturbance co‑exist [@1].

• Mirtazapine is considered the safest appetite stimulant for this population because it does not increase thromboembolic events or mortality, unlike megestrol acetate【strength: expert consensus】 [@2].
• Initiate at 7.5 mg at bedtime and titrate up to a maximum of 30 mg based on clinical response【strength: guideline recommendation】 [@4].
• Bedtime dosing leverages the drug’s sedating effect to improve sleep while stimulating appetite【strength: expert consensus】 [@4].
• Allow a 4–8‑week trial period before declaring treatment failure【strength: guideline recommendation】 [@4].
• Retrospective data show a mean weight gain of ~1.9 kg at 3 months and ~2.1 kg at 6 months, with about 80 % of patients experiencing some weight increase【strength: retrospective cohort】 [@2].
• Mirtazapine concurrently improves depression, insomnia, and appetite loss in this group【strength: expert consensus】 [@1].
• No thromboembolic risk has been reported, making it superior to megestrol acetate for patients with cardiovascular disease【strength: expert consensus】 [@2].
• Generally well‑tolerated; common beneficial side effects include sedation and appetite stimulation【strength: expert consensus】 [@4].
• Discontinue gradually over 10–14 days to avoid withdrawal symptoms【strength: expert consensus】 [@4].

Short‑Term Alternative: Dexamethasone

For patients with a *very limited life expectancy (weeks‑to‑a few months)*, dexamethasone 2–8 mg/day provides rapid appetite stimulation at lower cost [@1].

• Limit use to 1–3 weeks because of cumulative toxicity【strength: expert consensus】 [@2].
• Notable adverse effects include muscle wasting, insulin resistance, hyperglycemia, increased infection risk, and immunosuppression【strength: expert consensus】 [@1].
• In one trial, 36 % of patients stopped dexamethasone due to toxicity versus 25 % on megestrol acetate (p = 0.03)【strength: randomized trial】 [@2].

Third‑Line Option: Olanzapine

Olanzapine 5 mg/day may be considered when nausea or vomiting co‑exists, although evidence is limited [@2].

• In advanced cancer patients, olanzapine improved appetite scores from 1–2 to 6–8 on a 0–10 scale (p < 0.001)【strength: randomized trial】 [@2].
• When combined with megestrol acetate, 85 % achieved weight gain versus 41 % with megestrol alone【strength: exploratory trial】 [@2].

Agents to Avoid or Use With Caution

Special Population: Dementia

Do not prescribe pharmacologic appetite stimulants to patients with dementia unless they have concurrent depression【strength: consensus】 [@3].

• Clinical Nutrition guidelines reached 89 % consensus that appetite stimulants are not recommended for dementia patients due to limited evidence and safety concerns【strength: consensus】 [@3].

Monitoring and Reassessment

• Assess response at weeks 1, 2, 4, 8, and 12 after initiating therapy【strength: guideline recommendation】 [@4].
• Monitor for sedation (mirtazapine) and hyperglycemia (dexamethasone)【strength: expert consensus】 [@1].
• Document weight change, percentage of usual meal intake, and subjective appetite improvement.
• After 9 months of mirtazapine therapy, consider dose reduction to reassess ongoing need【strength: guideline recommendation】 [@4].
• Regularly weigh benefit versus harm as disease trajectory evolves【strength: expert consensus】 [@1].
• Discontinue if no meaningful response after an adequate trial (4‑8 weeks for mirtazapine; 1‑3 weeks for dexamethasone)【strength: expert consensus】 [@2].

General Recommendations

• Prior to pharmacotherapy, address reversible causes of anorexia (medication side effects, depression, poor dentition, dysphagia)【strength: expert consensus】 [@4].
• Do not expect lean muscle mass gain from any of these agents; weight gain is predominantly adipose tissue【strength: expert consensus】 [@2].
• For patients with cardiovascular risk, avoid megestrol acetate because of its elevated thromboembolic and mortality risks【strength: expert consensus】 [@2].
• Limit dexamethasone to ≤ 3 weeks to prevent cumulative toxicity【strength: expert consensus】 [@2].